Featured

Status

Health Topics

Any Category
Diseases
Neoplasms
Clear Filters

Search Clinical Trials

137 Results
Recruiting
Interleukin-15 Armored Glypican 3-specific Chimeric Antigen Receptor Expressed in Autologous T Cells for Solid Tumors
Approximately 118-27 subjects will participate in the treatment part of this study. Maximum of 180 mL of blood (approximately 12 tablespoons) is collected from patients to grow the T cells …
Baylor Role: Lead Sponsor
Recruiting
Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Histiocytic disorders are diseases caused by misfunctioning or buildup of particular immune cells called histiocytes. Many histiocytic disorders (LCH, juvenile xanthogranuloma (JXG), Erdheim-Chester disease (ECD), and Rosai-Dorfman Disease (RDD)) arises …
Baylor Role: Collaborator
Recruiting
Safety And Efficacy Of TKI Cessation For CML Patients With Stable Molecular Response In A Real World Population
Transitioning from busulfan, hydroxyurea, IFN-α to tyrosine kinase inhibitors (TKIs) has dramatically altered the natural history of CML. Patients with CML appropriately managed with TKIs are able to benefit from …
Baylor Role: Lead Sponsor
Recruiting
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
Treatment with CAdVEC: On the first day of your treatment, participants will receive an injection of CAdVEC into your tumor. A blood sample will be obtained from the participant before …
Baylor Role: Lead Sponsor
Recruiting
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Earlier, healthy donors gave blood for us to make CD30.CAR-EBVST cells in the laboratory. These cells were grown and frozen and the investigators will select the donor which the investigators …
Baylor Role: Lead Sponsor
Recruiting
Th-1 Dendritic Cell Immunotherapy Plus Standard Chemotherapy for Pancreatic Adenocarcinoma
The primary objective of this phase 1, first in man trial is to determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with pancreatic adenocarcinoma lysate …
Baylor Role: Lead Sponsor
Recruiting
Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen
To make the CLL1-CD28 chimeric antigen receptor T cells, the investigators will collect the patient's blood and stimulate them with growth factors to make the cells grow. To get the …
Baylor Role: Lead Sponsor
Recruiting
CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)
Earlier, a healthy donor provided blood to make ANCHOR cells in the laboratory. These cells were grown and frozen for later use. To make the ANCHOR cells, the investigators took …
Baylor Role: Lead Sponsor
Recruiting
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
The SentiNot 2.0 protocol aims to elucidate the effectivity and accuracy of the delayed sentinel lymph node dissection concept (dSLND) when upfront SLND is considered unnecessary, such as in the …
Baylor Role: Collaborator
Recruiting
C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)
To prepare the brain cancer specific GD2-C7R T cells, research staff will take some blood from the patient. The researchers will grow the GD2.C7R T cells by infecting the T …
Baylor Role: Lead Sponsor